4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxatetraconta-1,39-diyne

 CAS No.: 1351373-49-3  Cat No.: BP-500746  Purity: ≥95% 4.5  

This product, 4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxatetraconta-1,39-diyne, is a polyethylene glycol–like linker architecture featuring a long, repeating polyether chain terminated by two alkyne groups at the termini. Structurally, it provides a flexible, hydrophilic spacer that can span the distance between a ligand-bearing warhead and an E3 ligase–recruiting module while maintaining chemical handle(s) for site-specific conjugation. In PROTAC design, such bifunctional linkers enable controlled attachment strategies (for example, alkyne-based coupling to complementary partners) and help tune the effective intramolecular geometry, which is critical for productive ternary complex formation and subsequent ubiquitination. Its long chain length and ether-rich backbone can reduce steric mismatch and improve solubility of conjugates, facilitating synthesis and downstream biochemical evaluation. Overall, it is a useful building block for constructing and optimizing targeted protein degradation molecules where linker flexibility and spacing are key determinants of activity.

4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxatetraconta-1,39-diyne

Structure of 1351373-49-3

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
PROTAC Linker
Molecular Formula
C28H50O12
Molecular Weight
578.70
Appearance
Pale Yellow Oily Matter

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
≥95%
Solubility
Soluble in DCM, DMF, DMSO
Appearance
Pale Yellow Oily Matter
Storage
Store at 2-8°C
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]prop-1-yne
Synonyms
Bis-propargyl-PEG12; Bis-propargyl-PEG11
Boiling Point
593.3±45.0°C at 760 mmHg
Density
1.1±0.1 g/cm3
InChI Key
BTLUDNMRQXMTCO-UHFFFAOYSA-N
InChI
InChI=1S/C28H50O12/c1-3-5-29-7-9-31-11-13-33-15-17-35-19-21-37-23-25-39-27-28-40-26-24-38-22-20-36-18-16-34-14-12-32-10-8-30-6-4-2/h1-2H,5-28H2
SMILES
C#CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCC#C
1. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Emmanuel Mignot, David Mayleben, Ingo Fietze, Damien Leger, Gary Zammit, Claudio L A Bassetti, Scott Pain, Dalma Seboek Kinter, Thomas Roth; investigators Clinical TrialLancet Neurol. 2022 Feb;21(2):125-139.doi: 10.1016/S1474-4422(21)00436-1.
Background:Daytime functioning is impaired in people with insomnia disorder. Currently available dual orexin receptor antagonists have shown efficacy in insomnia disorder, but do not address all aspects of this disease. We aimed to assess safety and efficacy of daridorexant, a novel orexin receptor antagonist, on night-time and daytime symptoms of insomnia.
2. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
GBD0 Stroke Collaborators Lancet Neurol. 2021 Oct;20(10):795-820.doi: 10.1016/S1474-4422(21)00252-0.Epub 2021 Sep 3.
Background:Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels.
3. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang, Bo Hu, Chang Hu, Fangfang Zhu, Xing Liu, Jing Zhang, Binbin Wang, Hui Xiang, Zhenshun Cheng, Yong Xiong, Yan Zhao, Yirong Li, Xinghuan Wang, Zhiyong Peng JAMA. 2020 Mar 17;323(11):1061-1069.doi: 10.1001/jama.2020.1585.
Importance:In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of affected patients is limited. Objective:To describe the epidemiological and clinical characteristics of NCIP.Design, setting, and participants:Retrospective, single-center case series of the 138 consecutive hospitalized patients with confirmed NCIP at Zhongnan Hospital of Wuhan University in Wuhan, China, from January 1 to January 28, 2020; final date of follow-up was February 3, 2020.Exposures:Documented NCIP.Main outcomes and measures:Epidemiological, demographic, clinical, laboratory, radiological, and treatment data were collected and analyzed. Outcomes of critically ill patients and noncritically ill patients were compared. Presumed hospital-related transmission was suspected if a cluster of health professionals or hospitalized patients in the same wards became infected and a possible source of infection could be tracked. Results:Of 138 hospitalized patients with NCIP, the median age was 56 years (interquartile range, 42-68; range, 22-92 years) and 75 (54.3%) were men. Hospital-associated transmission was suspected as the presumed mechanism of infection for affected health professionals (40 [29%]) and hospitalized patients (17 [12.3%]). Common symptoms included fever (136 [98.6%]), fatigue (96 [69.6%]), and dry cough (82 [59.4%]). Lymphopenia (lymphocyte count, 0.8 × 109/L [interquartile range {IQR}, 0.6-1.1]) occurred in 97 patients (70.3%), prolonged prothrombin time (13.0 seconds [IQR, 12.3-13.7]) in 80 patients (58%), and elevated lactate dehydrogenase (261 U/L [IQR, 182-403]) in 55 patients (39.9%). Chest computed tomographic scans showed bilateral patchy shadows or ground glass opacity in the lungs of all patients. Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%]). Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%]). The median time from first symptom to dyspnea was 5.0 days, to hospital admission was 7.0 days, and to ARDS was 8.0 days. Patients treated in the ICU (n = 36), compared with patients not treated in the ICU (n = 102), were older (median age, 66 years vs 51 years), were more likely to have underlying comorbidities (26 [72.2%] vs 38 [37.3%]), and were more likely to have dyspnea (23 [63.9%] vs 20 [19.6%]), and anorexia (24 [66.7%] vs 31 [30.4%]). Of the 36 cases in the ICU, 4 (11.1%) received high-flow oxygen therapy, 15 (41.7%) received noninvasive ventilation, and 17 (47.2%) received invasive ventilation (4 were switched to extracorporeal membrane oxygenation). As of February 3, 47 patients (34.1%) were discharged and 6 died (overall mortality, 4.3%), but the remaining patients are still hospitalized. Among those discharged alive (n = 47), the median hospital stay was 10 days (IQR, 7.0-14.0).Conclusions and relevance:In this single-center case series of 138 hospitalized patients with confirmed NCIP in Wuhan, China, presumed hospital-related transmission of 2019-nCoV was suspected in 41% of patients, 26% of patients received ICU care, and mortality was 4.3%.

4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxatetraconta-1,39-diyne is a long-chain, homobifunctional polyether linker containing a terminal propargyl group at each end. Its extended PEG-like backbone provides substantial conformational flexibility and separates the two reactive alkyne termini. The linker can support the assembly of conjugates requiring a long, polar spacer and two independently addressable click-chemistry handles.

Structure: The molecule comprises a long polyether chain flanked by two terminal propargyl groups. Its carbon–carbon triple bonds are positioned at opposite ends of the chain and are separated by multiple saturated ethylene glycol units; they are therefore neither adjacent nor conjugated. The repeated ether linkages contribute polarity and rotational freedom, making the backbone flexible rather than intrinsically rigid or conformationally fixed.

Reactivity: Both terminal alkynes are suitable for copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) with azide-functionalized ligands or other molecular components. The homobifunctional design enables symmetrical double conjugation or stepwise preparation of unsymmetrical products. When two different azide-bearing partners are introduced, sequential reaction and purification of the mono-substituted intermediate can improve control over product composition. Reaction conditions should also be selected to preserve sensitive groups on the conjugation partners.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code
Inquiry Basket